Stock Analiz

CervoMed Inc. CRVO

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$1.69Market cap $26M
Open the interactive analysis →

CervoMed Inc. (CRVO) is a healthcare company listed in the US with a market value of about $26M. In the twelve months to September 30, 2026 it had revenue of $8726 and net income of -$29M, a net margin of -326822.5%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -78%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.

About CervoMed

CervoMed is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 10 years in our data. Its share count rose by 1645% over three years (dilution for shareholders). It spends 545% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S2,930.0
P/B1.5
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−100%

Growth and quality

Revenue growth (1 yr)-58.9%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-290.2%
ROIC (5-yr avg.)-78.1%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$8726$4M$10M$7M$0——————
Net income-$29M-$27M-$16M-$2M-$6M-$24M-$14M-$12M-$18M-$1M-$18M
Free cash flow—————————-$13M-$11M
EPS (diluted)$-2.77$-2.98$-2.02$-0.82$2038891.00$1946859.00$53831973.00$6706509.00$3242301.00$-29.11$-26.47
Net margin-326822.5%-673.1%-167.3%-30.4%———————
ROIC—-122.7%-36.7%-83.7%—-69.4%-57.2%-44.8%-118.6%-29.4%-155.0%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is CervoMed stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does CervoMed pay a dividend?

Not currently.

Is CervoMed a good stock to buy?

We do not give buy or sell advice. CervoMed scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.